Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
HC: healthy controls; RA: rheumatoid arthritis; OA: osteoarthritis; SLE: systemic lupus erythematosus; SSc: systemic scleroderma; AS: ankylosing spondylitis; pSS: primary Sjogren syndrome; MCTD: mixed connective tissue diseaseDemographic characteristics of participantsHCRAPaOAPaSLEPaSScPaN = 302N = 559N = 198N = 206N = 53Age, years, median [IQR]63.0 [53.2;72.8]58.0 [50.0;66.0]< 0.00161.0 [53.0;69.8]0.18845.0 [35.0;54.0]< 0.00154.0 [45.0;59.0]< 0.001Disease durationb, years, median [IQR]NA5.6 [2.0;12.0]NA4.0 [1.5;10.0]NA3.0 [1.0;7.0]NA3.5 [2.0;7.0]NAAge groups, years, n(%)< 0.0010.008< 0.0010.019 < 3019 (6.3)10 (1.8)2 (1.0)37 (18.0)2 (3.8) 31 to 399 (3.0)24 (4.2)4 (2.0)38 (18.4)5 (9.4) 40 to 4925 (8.3)105 (18.8)29 (14.6)50 (24.3)10 (18.9) ≥ 50249 (82.5)420 (75.1)163 (82.3)81 (39.3)36 (67.9)BMI, Kg/m2, mean (SD)22.5 (3.7)21.9 (3.5)0.32124.1 (4.0)< 0.00122.0 (3.6)0.08521.8 (3.0)0.935Gender, female, n(%)229 (75.8)450 (80.5)0.173165 (83.3)0.087187 (90.8)< 0.00138 (71.7)0.676Menopause status of female, n(%)0.010.277< 0.0010.067 Post-menopause202 (88.2)359 (79.8)139 (84.2)91 (48.7)29 (76.3) Early menopause, age ≤ 4531 (15.3)48 (13.4)18 (12.9)18 (19.8)4 (13.8)HCASPapSSPaGoutPaMCTDPaN = 302N = 128N = 98N = 111N = 45Age, years, median [IQR]63.0 [53.2;72.8]36.5 [27.0;45.2]< 0.00154.5 [46.0;60.0]< 0.00161.0 [48.0;72.0]0.26956.0 [46.0;62.0]< 0.001Disease durationb, years, median [IQR]NA6.5 [3.0;12.0]NA1.2 [0.6;2.3]NA6.0 [3.0;11.5]NA1.3 [0.5;4.5]NAAge groups, years, n(%)< 0.0010.0030.0060.003 < 3019 (6.3)42 (32.8)5 (5.1)5 (4.5)2 (4.4%) 31 to 399 (3.0)30 (23.4)10 (10.2)7 (6.31)2 (4.4) 40 to 4925 (8.3)36 (28.1)17 (17.3)22 (19.8)13 (28.9) ≥ 50249 (82.5)20 (15.6)66 (67.3)77 (69.4)28 (62.2)BMI, Kg/m2, mean (SD)22.5 (3.7)22.0 (4.2)0.86521.3 (2.9)0.09424.1 (3.3)0.00321.6 (3.0)0.79Gender, female, n(%)229 (75.8)40 (31.2)< 0.00191 (92.9)0.00118 (16.2)< 0.00139 (86.7)0.197Menopause status of female, n(%)< 0.0010.0010.7340.001 Post-menopause202 (88.2)9 (22.5)66 (72.5)17 (94.4)26 (66.7) Early menopause, age ≤ 4531 (15.3)3 (33.3)5 (7.6)5 (29.4)7 (26.9)aCompared with healthy controls. b:correlated with ageHC healthy controls, RA rheumatoid arthritis, OA osteoarthritis, SLE systemic lupus erythematosus, SSc systemic scleroderma, AS ankylosing spondylitis, pSS primary Sjogren syndrome, MCTD mixed connective tissue diseaseBaseline characteristics of all patientsCharacteristicResultsFormer or current smoking, n(%)151 (8.9)Always drinking, n(%)107 (6.3)Comorbidities, n(%) Diabetes Mellitus203 (11.9) Hypertension424 (24.9) Dyslipidemia284 (16.7) Hyperuricemia395 (23.2) Hypovitaminosis D1167 (68.6)Complications, n(%) Femoral head necrosis28 (1.6) Osteoporotic fracture75 (4.4)Medication history, yes, n(%) Former or current chronic oral Glucocorticoid therapy713 (41.9) NSAIDs799 (47.0) cDMARDs 1 Type261 (15.5) 2 Types336 (20.0) 3 Types124 (7.4) bDMARDs112 (6.6)Blood calcium level, mean (SD)2.6 (7.8)Serum phosphate level, mean (SD)1.3 (2.6)Serum creatinine level, median [IQR]62.0 [53.0, 75.3]Serum Uric acid level, n(%) < 3601068 (63.6) 360 to 419249 (14.8) 420 ~ 539243 (14.5) ≥540118 (7.0)CRP, median [IQR]7.1 [1.5, 30.9]ESR, median [IQR]34.5 [15.0, 66.0]Serum 25(OH)D3 level, mean (SD)64.0 (26.3)Elevated inflammatory markers, n(%) ESR972 (63.8) CRP729 (47.8)NSAIDs non-steroidal anti-inflammatory drugs, cDMARDs conventional disease-modifying anti-rheumatic drugs, bDMARDs biological disease-modifying anti-rheumatic drugs, ESR erythrocyte sedimentation rate, CRP c-reactive protein
Source: Baseline characteristics of patients. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
An analytical cross-sectional study design was carried out, and rheumatic in-patients were consecutively recruited considering individual classification criteria from the rheumatism departments in four hospitals from May 2017 to August 2018.
Source: Methods.
An analytical cross-sectional study design was carried out, and rheumatic in-patients were consecutively recruited considering individual classification criteria from the rheumatism departments in four hospitals from May 2017 to August 2018.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Prevalence and risk factors for bone loss in Southern Chinese with rheumatic diseases
Cross-sectional study · BMC Musculoskeletal Disorders · 2020
Original publication title
Prevalence and risk factors for bone loss in Southern Chinese with rheumatic diseases
© The Author(s) 2020
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What methods does the paper describe?
A cross-sectional study recruits 1398 rheumatic patients and 302 healthy subjects. Demographic data, blood, and bone mineral density (BMD) tests are collected. Risk factors for bone loss in rheumatic patients are analyzed by logistic regression.
Source: MethodAbstract: Backgroud
This study is to explore the prevalence of different stages of bone loss and the potential risk factors in rheumatic patients.
Source: BackgroudAbstract: Results
(1) Rheumatic patients are consisted of 40.0% rheumatoid arthritis (RA), 14.7% systemic lupus erythematosus (SLE), 14.2% osteoarthritis (OA), 9.2% ankylosing spondylosis (AS), 7.9% gout, 7.0% primary Sjogren syndrome (pSS), 3.8% systemic sclerosis (SSc), and 3.2% mixed connective tissue disease (MCTD). (2) In male patients aged under 50 and premenopausal female patients, the bone mineral density score of AS (53.9%, P < 0.001) and SLE (39.6%, P = 0.034) patients is lower than the healthy controls (18.2%). (3) Osteopenia and osteoporosis are more prevailing in male patients aged or older than 50 and postmenopausal female patients with RA (P < 0.001), OA (P = 0.02) and SLE (P = 0.011) than healthy counterparts. (4) Those with SLE, RA and AS gain the highest odd ratio of ‘score below the expected range for age’, osteopenia and osteoporosis, respectively. (5) Age, female, low BMI and hypovitaminosis D are found negatively associated with bone loss.
Dyslipidemia and hyperuricemia could be protective factors.
Source: ResultsAbstract: Conclusion
Young patients with AS and SLE have a significant higher occurrence of bone loss, and older patients with RA, OA and SLE had higher prevalence than healthy counterparts. SLE, RA, SSc and AS were founded significant higher risks to develop into bone loss after adjustment. Age, BMI and gender were commonly-associated with bone loss in all age-stratified rheumatic patients. These findings were not markedly different from those of previous studies.
Source: ConclusionAuthors’ abstract
Backgroud
This study is to explore the prevalence of different stages of bone loss and the potential risk factors in rheumatic patients.
Method
A cross-sectional study recruits 1398 rheumatic patients and 302 healthy subjects. Demographic data, blood, and bone mineral density (BMD) tests are collected. Risk factors for bone loss in rheumatic patients are analyzed by logistic regression.
Results
(1) Rheumatic patients are consisted of 40.0% rheumatoid arthritis (RA), 14.7% systemic lupus erythematosus (SLE), 14.2% osteoarthritis (OA), 9.2% ankylosing spondylosis (AS), 7.9% gout, 7.0% primary Sjogren syndrome (pSS), 3.8% systemic sclerosis (SSc), and 3.2% mixed connective tissue disease (MCTD). (2) In male patients aged under 50 and premenopausal female patients, the bone mineral density score of AS (53.9%, P < 0.001) and SLE (39.6%, P = 0.034) patients is lower than the healthy controls (18.2%). (3) Osteopenia and osteoporosis are more prevailing in male patients aged or older than 50 and postmenopausal female patients with RA (P < 0.001), OA (P = 0.02) and SLE (P = 0.011) than healthy counterparts. (4) Those with SLE, RA and AS gain the highest odd ratio of ‘score below the expected range for age’, osteopenia and osteoporosis, respectively. (5) Age, female, low BMI and hypovitaminosis D are found negatively associated with bone loss.
Dyslipidemia and hyperuricemia could be protective factors.
Conclusion
Young patients with AS and SLE have a significant higher occurrence of bone loss, and older patients with RA, OA and SLE had higher prevalence than healthy counterparts. SLE, RA, SSc and AS were founded significant higher risks to develop into bone loss after adjustment. Age, BMI and gender were commonly-associated with bone loss in all age-stratified rheumatic patients. These findings were not markedly different from those of previous studies.
Publication and source details
Original title: Prevalence and risk factors for bone loss in Southern Chinese with rheumatic diseases
Zhuoran Hu; Shuiming Xu; He Lin; Weifeng Ni; Qingyuan Yang; Jun Qi; Keqian Du; Jieruo Gu; Zhiming Lin
BMC Musculoskeletal Disorders · 2020
© The Author(s) 2020https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.http://dx.doi.org/10.13039/501100012243Foundation for Distinguished Young Talents in Higher Education of Guangdong2014A030306039Lin Zhiming High-level personnel of special support program for Technology Innovative Talents and the Top Young of Guangdong Province2015TQ01R516Lin Zhiming Distinguished Young Scholar Candidates Programme for The Third Affiliated Hospital of Sun Yat-Sen University and Pearl River Nova Program of Guangzhou201610010005Lin ZhimingRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T17:34:10.640092+00:00
DOI: 10.1186/s12891-020-03403-1 · PMC7329556